CP-122721

DB05421ExperimentalSmall molecule

CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

Mechanism: CP-122721 interacts with high affinity at the human NK1 receptor expressed in IM-9 cells.
Curator reviewed
Primary indication: Investigated for use/treatment in asthma, depression, and irritable bowel syndrome (IBS).Curator reviewed
Formula / weight: C₂₀H₂₃F₃N₂O₂ · 380.404 g/mol (avg)
Code names: (+)-CP-122,721

Resolves to

Compound

UNIIR7OYP6N58FCAS145742-28-5ChEMBLCHEMBL319118PubChem9821217

Structure

InChIKeyZIWFCOIGUNPHPM-HKUYNNGSSA-NSMILESCOC1=CC=C(OC(F)(F)F)C=C1CN[C@H]1CCCN[C@H]1C1=CC=CC=C1

Targets

P25103TACR1

What you can answer from here — as of March 06, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with CP-122721, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account